{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-029397","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2021-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.547593+00:00","generated_at":"2026-06-28T06:40:40.957558+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SAB Biotherapeutics appoints Samuel J. Reich as Executive Chairman; $350K salary, 350K share option.","bullets":["Reich named Executive Chairman effective Oct 25, 2021; reports to Board of Directors.","Annual base salary of $350,000; eligible for annual cash bonus of at least 50% of base salary.","Granted nonqualified stock option for 350,000 shares vesting over three years (1/3 year 1, remainder monthly).","Severance: 12 months salary + COBRA if terminated without cause/good reason; 24 months if in change of control period.","Agreement includes standard restrictive covenants (non-disclosure, non-compete, non-solicitation)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-029397","json":"https://secwatch.observer/filing/0001493152-21-029397.json","markdown":"https://secwatch.observer/filing/0001493152-21-029397.md","text":"https://secwatch.observer/filing/0001493152-21-029397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221029397/0001493152-21-029397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221029397/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T06:40:40.957558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e98e886a0","claim":"Samuel J. Reich was appointed as Executive Chairman of the Board of Directors at SAB Biotherapeutics, Inc..","evidence_excerpt":"On November 17, 2021, and effective as of October 25, 2021, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into an Executive Employment Agreement with Mr. Samuel J. Reich (the “Agreement”) to serve as the Company’s Executive Chairman of the Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221029397/0001493152-21-029397-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}